Werewolf Therapeutics, Inc. (NASDAQ: HOWL) has received a consensus recommendation of “Hold” from analysts covering the biotechnology firm, according to MarketBeat. The average twelve-month price target established by these brokerages is set at $3.75. Among the eight brokerages, one has rated the stock as a sell, four have issued hold recommendations, and three have assigned buy ratings.
Research analysts have been actively revising their outlook on Werewolf Therapeutics. Notably, HC Wainwright lowered its target price from $10.00 to $4.00, while maintaining a “buy” rating in a report released on December 19, 2023. Citizens JMP also adjusted its stance, downgrading the stock from a “strong-buy” to a “hold” on the same date. On November 18, 2023, Bank of America revised its price objective from $8.00 to $7.00, while keeping a “buy” rating. Similarly, Wedbush downgraded the stock from an “outperform” rating to “neutral,” setting a target price of $1.00. Weiss Ratings reiterated a “sell (D-)” rating in a report dated October 8, 2023.
Institutional Investors Make Moves
Recent changes in institutional investor positions highlight a shifting landscape for Werewolf Therapeutics. MPM Asset Management LLC increased its holdings by 0.6% in the first quarter, now owning 4,309,860 shares valued at approximately $4.19 million after acquiring an additional 25,688 shares. Similarly, MPM Bioimpact LLC raised its stake by 0.9%, ending the quarter with 2,408,810 shares worth around $2.34 million.
Bank of America Corp DE also enhanced its position, growing its stake by 1.2% during the second quarter, now holding 2,129,024 shares valued at about $2.32 million. In another notable investment, Vanguard Group Inc. increased its holdings by 8.5% in the third quarter, now owning 1,408,047 shares worth approximately $2.77 million. Overall, institutional investors own approximately 64.84% of the stock.
Current Stock Performance
As of Monday, shares of Werewolf Therapeutics opened at $0.64. The company’s fifty-day moving average price stands at $0.98, while the two-hundred day moving average price is $1.27. With a market capitalization of $31.30 million, the firm has a price-to-earnings ratio of -0.40 and a beta of 0.77. The stock has experienced a 52-week low of $0.56 and a 52-week high of $2.38. Additionally, Werewolf Therapeutics has a debt-to-equity ratio of 0.73 and both a quick and current ratio of 3.87.
In its most recent quarterly earnings report, released on November 4, 2023, Werewolf Therapeutics reported earnings per share (EPS) of ($0.36), surpassing the consensus estimate of ($0.39) by $0.03. Analysts predict that the company will post an EPS of ($1.56) for the current year.
Werewolf Therapeutics, Inc. focuses on developing next-generation immunotherapies aimed at treating solid tumors. The company employs a proprietary Conditional Activation Platform, which is designed to keep therapeutic molecules inactive in healthy tissues and activate them selectively within the tumor microenvironment. This approach aims to enhance anti-tumor efficacy while reducing systemic toxicity. The company is advancing multiple programs, including conditionally activated cytokine candidates and bi-specific antibody constructs.
